Literature DB >> 32430352

Romiplostim for management of refractory immune thrombocytopenic purpura in the immediate postpartum period.

Ariana Patras1, Reinaldo Figueroa1, Amit P Singh2,3, Ichchha Madan4.   

Abstract

We present a case of a pregnant woman with chronic immune thrombocytopenic purpura and chronic hypertension who developed pre-eclampsia with severe features warranting delivery. Her overall clinical picture and liver enzymes improved in the immediate postpartum period, however, aggressively progressing thrombocytopenia posed a diagnostic dilemma to the interdisciplinary care team. After failing to respond to first-line therapies including high-dose corticosteroids and intravenous immunoglobulin, she was successfully managed with a trial of the thrombopoietin receptor agonist, Romiplostim. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  haematology (incl blood transfusion); obstetrics, gynaecology and fertility; pregnancy

Mesh:

Substances:

Year:  2020        PMID: 32430352      PMCID: PMC7239498          DOI: 10.1136/bcr-2020-234335

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

1.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

Review 2.  ACOG Practice Bulletin No. 107: Induction of labor.

Authors: 
Journal:  Obstet Gynecol       Date:  2009-08       Impact factor: 7.661

Review 3.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Authors:  Cindy Neunert; Wendy Lim; Mark Crowther; Alan Cohen; Lawrence Solberg; Mark A Crowther
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

Review 4.  Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.

Authors:  Katie Atkinson
Journal:  Clin J Oncol Nurs       Date:  2019-04-01       Impact factor: 1.027

5.  Use of romiplostim in pregnancy for refractory idiopathic thrombocytopenic purpura: Two case reports with maternal and fetal outcomes and literature review.

Authors:  Su J Chua; Mark R Morton; John Svigos; David M Ross; Simon Kane
Journal:  Obstet Med       Date:  2018-05-29

6.  Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.

Authors:  James B Bussel; David J Kuter; Vinod Pullarkat; Roger M Lyons; Matthew Guo; Janet L Nichol
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

Review 7.  International consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Roberto Stasi; Adrian C Newland; Victor S Blanchette; Paula Bolton-Maggs; James B Bussel; Beng H Chong; Douglas B Cines; Terry B Gernsheimer; Bertrand Godeau; John Grainger; Ian Greer; Beverley J Hunt; Paul A Imbach; Gordon Lyons; Robert McMillan; Francesco Rodeghiero; Miguel A Sanz; Michael Tarantino; Shirley Watson; Joan Young; David J Kuter
Journal:  Blood       Date:  2009-10-21       Impact factor: 22.113

Review 8.  Placenta derived factors involved in the pathogenesis of the liver in the syndrome of haemolysis, elevated liver enzymes and low platelets (HELLP): A review.

Authors:  L C E W van Lieshout; G H Koek; M A Spaanderman; P J van Runnard Heimel
Journal:  Pregnancy Hypertens       Date:  2019-08-19       Impact factor: 2.899

Review 9.  The Differential Diagnosis of Thrombocytopenia in Pregnancy.

Authors:  Frauke Bergmann; Werner Rath
Journal:  Dtsch Arztebl Int       Date:  2015-11-20       Impact factor: 5.594

Review 10.  Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.

Authors:  Hanny Al-Samkari; David J Kuter
Journal:  Ther Adv Hematol       Date:  2019-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.